|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 100 DAINGERFIELD ROAD |
Address2 | 3rd FLOOR |
City | ALEXANDRIA |
State | VA |
Zip Code | 22314 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 27478-12
|
||||||||
|
6. House ID# 303540000
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Karry La Violette |
Date | 4/17/2020 10:44:24 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
H.R. 127, CARERS Act of 2019;
H.R. 171, the Legitimate Use of Medical Marihuana Act;
H.R. 1845, ALERT Act of 2019;
S. 516, Prescription Drug Monitoring Act of 2019;
H.R. 1588, Ending Federal Marijuana Prohibition Act of 2019;
Implementation of pharmacy provisions of Public Law No: 115-271;
Implementation of Hemp provisions of Public Law No: 115-334;
H.R. 4810, the Opioid Prescription Verification Act of 2019;
S. 3070, the Preventing Pill Mills Through Data Sharing Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Ronna |
Hauser |
|
|
|
Phillip |
Harbison |
|
|
|
Anne |
Cassity |
|
|
|
Reema |
Taneja |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
H.R. 1607, Fairness to Pet Owners Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Ronna |
Hauser |
|
|
|
Phillip |
Harbison |
|
|
|
Anne |
Cassity |
|
|
|
Reema |
Taneja |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S. 474, Stop the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act;
H.R. 447 / S. 97, Affordable and Safe Prescription Drug Importation Act;
S. 61 / H.R. 478, Safe and Affordable Drugs from Canada Act of 2019;
S. 102 / H.R. 465, Prescription Drug Price Relief Act of 2019;
H.R.1478, Affordable Insulin Act of 2019;
S. 3, Keeping Health Insurance Affordable Act of 2019;
H.R 965 / S. 340, CREATES Act of 2019;
H.R. 1332, Fair Care Act of 2019;
S. 637, CURE High Drug Prices Act;
H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019;
S. 657, A bill to amend title XXVII of the Public Health Service Act to establish requirements with respect to prescription drug benefits;
S. 709, Prescription Drug Pricing Dashboard Act;
S. 977, Transparent Drug Pricing Act of 2019;
S. 1895, Lower Health Care Costs Act;
H.R. 2296, FAIR Drug Pricing Act of 2019;
H.R. 3947, the Competition Prescription Act of 2019;
H.R. 2279, the Safe Step Act;
H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act;
S. 2543, the Prescription Drug Pricing Reduction Act of 2019;
H.R. 19 / S. 3129, the Lower Costs, More Cures Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), White House Office, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Ronna |
Hauser |
|
|
|
Phillip |
Harbison |
|
|
|
Anne |
Cassity |
|
|
|
Reema |
Taneja |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 803 / S. 988, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act;
H.R. 1034 / S. 640, Phair Pricing Act of 2019;
H.R. 1035, Prescription Drug Price Transparency Act,
S. 475, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act,
S. 476, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act;
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs;
H.R.448 / S. 99, Medicare Drug Price Negotiation Act;
H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019;
H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019;
H.R. 366, Insulin Access for All Act of 2019;
S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019;
S. 205 / H.R. 937, Right Rebate Act of 2019;
H.R. 1046 / S. 377, Medicare Negotiation and Competitive Licensing Act of 2019;
H.R. 1781 / S. 801, the Payment Commission Data Act of 2019;
H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act of 2019;
H.R. 2115, To amend title XI of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers;
Proposed rule, "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS-4180-P";
Proposed rule, "Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, OIG-0936-P";
Proposed rule, Medicaid Program; Medicaid and Childrens Health Insurance Plan (CHIP) Managed Care - CMS-2408-P;
H.R. 1323, Rural Hospital Frontier Fairness Act;
S. 551, REFUND Act of 2019;
S. 691, Medicare Extra Rx HELP Act of 2019;
S. 773, Telehealth Innovation and Improvement Act of 2019;
S. 814, Expanding Access to Diabetes Self-Management Training Act of 2019;
H.R. 1384 / S. 1129, Medicare for All Act of 2019;
H.R. 3417, The Beneficiary Education Tools, Telehealth, and Extenders Reauthorization Act of 2019;
H.R. 3408, Shop Rx Act of 2019;
S. 1384, Prescription Drug Rebate Reform Act of 2019;
H.R. 2113, Prescription Drug STAR Act;
H.R. 2115, Public Disclosure of Drug Discounts Act
S. 2447, the Phair Relief Act;
S. 2771, the Protecting Home Oxygen and Medical Equipment Act of 2019;
S. 1861 / H.R. 3924, the Streamlining Part D Appeals Process Act;
H.R. 4946, the Ensuring Seniors Access to Local Pharmacies Act of 2019;
H.R. 5281, the Drug Price Transparency in Medicaid Act of 2019;
H.R. 5442, the Lowest Price for Patients Act;
Report language for H.R.1865, the Further Consolidated Appropriations Act;
Pharmacist Provider Status draft legislation
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Government Accountability Office (GAO), Medicare Payment Advisory Commission (MedPAC), Small Business Administration (SBA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Ronna |
Hauser |
|
|
|
Phillip |
Harbison |
|
|
|
Anne |
Cassity |
|
|
|
Reema |
Taneja |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019;
H.R. 2376 / S. 1227, Prescription Pricing for the People Act of 2019;
H.R. 3223 / S. 1532, Pharmacy Benefit Manager Accountability Study Act of 2019;
H.R. 5198, the Patients' Right to Know Their Medication Act of 2019;
H.R. 5304, the PBM Transparency in Prescription Drug Costs Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Ronna |
Hauser |
|
|
|
Phillip |
Harbison |
|
|
|
Anne |
Cassity |
|
|
|
Reema |
Taneja |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
S. 172/H.R. 1398, Health Insurance Tax Relief Act of 2019;
S. 215/H.R. 218, Death Tax Repeal Act of 2019;
S. 1089/ H.R. 1922, Restoring Access to Medication Act of 2019;
Final rule on Qualified Business Income Deduction;
S. 1149/H.R. 216, the Main Street Tax Certainty Act of 2019;
S. 3548, the Coronavirus Aid, Relief, and Economic Security (CARES) Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), White House Office, Small Business Administration (SBA), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Phillip |
Harbison |
|
|
|
Karry |
La Violette |
|
|
|
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Reema |
Taneja |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
Tricare pharmacy issues;
FY21 National Defense Authorization Act draft legislation
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Defense - Dept of (DOD)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Phillip |
Harbison |
|
|
|
Ronna |
Hauser |
|
|
|
Karry |
La Violette |
|
|
|
Reema |
Taneja |
|
|
|
Anne |
Cassity |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
Final rule, "Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees";
H.R. 6201, the Families First Coronavirus Response Act
17. House(s) of Congress and Federal agencies Check if None
Labor - Dept of (DOL), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Phillip |
Harbison |
|
|
|
Reema |
Taneja |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Rutledge v. Pharmaceutical Care Management Association; pet. for cert. granted, No.18-540 (U.S.)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Phillip |
Harbison |
|
|
|
Karry |
La Violette |
|
|
|
Anne |
Cassity |
|
|
|
Reema |
Taneja |
|
|
|
Ronna |
Hauser |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |